“
TL;DR
This single-arm phase 2a study evaluated the safety and anti-tumor activity of the microtubule-targeting agent lisavanbulin administered as a 48-hour IV infusion at 70 mg/m² in 23 patients with ovarian cancer or recurrent glioblastoma.
Investigational New Drugs · 11 authors, 9 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This single-arm phase 2a study evaluated the safety and anti-tumor activity of the microtubule-targeting agent lisavanbulin administered as a 48-hour IV infusion at 70 mg/m² in 23 patients with ovarian cancer or recurrent glioblastoma.
The 48-hour infusion was designed to reduce the vascular toxicity associated with peak serum concentrations seen with a prior 2-hour infusion schedule. In the ovarian cancer cohort, three patients achieved stable disease as best response with lesion size reductions after two cycles. In the glioblastoma cohort, one patient achieved partial response (treated for 16 cycles) and one achieved stable disease (treated for 10 cycles), yielding a disease control rate of 25% and an objective response rate of 12.5%. Most patients (95.7%) reported at least one treatment-emergent adverse event; the most common were fatigue (43.5%), constipation (34.8%), decreased appetite (30.4%), and abdominal pain (26.1%).